| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
6,530,000 |
| Market
Cap: |
6.21(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.9 - $1.94 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Organovo Holdings is a biotechnology company that focuses on building 3D tissues that recapitulate main aspects of human disease. Co. uses these models to identify gene targets responsible for driving the disease and intend to initiate drug discovery programs around these validated targets. Co.'s NovoGen Bioprinters® are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Co.'s NovoGen Bioprinters® can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Co.'s NovoGen Bioprinters® also serve as components of its tissue prototyping and manufacturing platform.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
19,607 |
19,607 |
19,607 |
| Total Sell Value |
$0 |
$31,750 |
$31,750 |
$31,750 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
1 |
1 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Murphy Keith |
Chairman, CEO and President |
• • – |
2017-02-08 |
4 |
OE |
$1.00 |
$30,000 |
I/I |
30,000 |
6,068,915 |
|
- |
|
| Murphy Keith |
Chairman, CEO and President |
• • – |
2017-01-24 |
4 |
AS |
$3.50 |
$70,440 |
D/D |
(20,100) |
6,038,915 |
|
- |
|
| Murphy Keith |
Chairman, CEO and President |
• • – |
2017-01-23 |
4 |
AS |
$3.51 |
$17,215 |
D/D |
(4,900) |
6,059,015 |
|
- |
|
| Murphy Keith |
Chairman, CEO and President |
• • – |
2016-12-14 |
4 |
AS |
$3.72 |
$185,955 |
D/D |
(50,000) |
6,063,915 |
|
- |
|
| Presnell Sharon Collins |
Chief Scientific Officer |
• – – |
2016-11-16 |
4 |
D |
$3.26 |
$3,944 |
D/D |
(1,210) |
116,745 |
|
- |
|
| Murphy Keith |
Chairman, CEO and President |
• • – |
2016-11-16 |
4 |
D |
$3.26 |
$23,468 |
D/D |
(7,200) |
6,113,915 |
|
- |
|
| Gallant Paul |
General Manager |
• – – |
2016-11-16 |
4 |
D |
$3.26 |
$3,781 |
D/D |
(1,160) |
45,375 |
|
- |
|
| David Eric |
CSO & EVP Pre-Clinical Dev |
• – – |
2016-11-16 |
4 |
D |
$3.26 |
$5,688 |
D/D |
(1,745) |
703,356 |
|
- |
|
| Bush Jennifer |
General Counsel & Secretary |
• – – |
2016-11-16 |
4 |
D |
$3.26 |
$3,944 |
D/D |
(1,210) |
47,576 |
|
- |
|
| Murphy Keith |
Chairman, CEO and President |
• • – |
2016-09-16 |
4 |
D |
$4.00 |
$5,576 |
D/D |
(1,394) |
6,121,115 |
|
- |
|
| Kussman Craig |
Chief Financial Officer |
• – – |
2016-08-23 |
4 |
A |
$0.00 |
$0 |
D/D |
132,000 |
132,000 |
|
- |
|
| Presnell Sharon Collins |
Chief Scientific Officer |
• – – |
2016-08-19 |
4 |
D |
$4.00 |
$4,438 |
D/D |
(1,109) |
117,955 |
|
- |
|
| Gallant Paul |
General Manager |
• – – |
2016-08-19 |
4 |
D |
$4.00 |
$3,862 |
D/D |
(965) |
46,535 |
|
- |
|
| David Eric |
CSO & EVP Pre-Clinical Dev |
• – – |
2016-08-19 |
4 |
D |
$4.00 |
$4,822 |
D/D |
(1,205) |
705,101 |
|
- |
|
| Murphy Keith |
Chairman, CEO and President |
• • – |
2016-08-19 |
4 |
D |
$4.00 |
$20,525 |
D/D |
(5,129) |
6,122,509 |
|
- |
|
| Bush Jennifer |
General Counsel & Secretary |
• – – |
2016-08-19 |
4 |
D |
$4.00 |
$4,858 |
D/D |
(1,214) |
48,786 |
|
- |
|
| Howson Tamar D |
Director |
– • – |
2016-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
7,500 |
|
- |
|
| Kessel Mark |
Director |
– • – |
2016-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Maroun Richard E |
Director |
– • – |
2016-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Malloy Kirk |
Director |
– • – |
2016-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
7,500 |
|
- |
|
| Glover James T |
Director |
– • – |
2016-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
17,500 |
|
- |
|
| Baltera Robert Jr. |
Director |
– • – |
2016-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
146,006 |
|
- |
|
| David Eric |
CSO & EVP Pre-Clinical Dev |
• – – |
2016-08-05 |
4 |
AS |
$4.55 |
$91,000 |
D/D |
(20,000) |
706,306 |
|
- |
|
| Murphy Keith |
Chairman, CEO and President |
• • – |
2016-07-11 |
4 |
A |
$0.00 |
$0 |
D/D |
208,000 |
6,127,638 |
|
- |
|
| Presnell Sharon Collins |
Chief Scientific Officer |
• – – |
2016-07-11 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
119,064 |
|
- |
|
151 Records found
|
|
Page 5 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.03 (2.92%) 
